Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.

Reiner, Anne S; Durham, Benjamin H; Yabe, Mariko; Petrova-Drus, Kseniya; Francis, Jasmine H; Rampal, Raajit K; Lacouture, Mario E; Rotemberg, Veronica; Abdel-Wahab, Omar; Panageas, Katherine S; Diamond, Eli L.

Affiliation

Reiner AS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Durham BH; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yabe M; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Petrova-Drus K; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Francis JH; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rampal RK; Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lacouture ME; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rotemberg V; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abdel-Wahab O; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Panageas KS; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Diamond EL; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Br J Haematol ; 203(3): 389-394, 2023 11.

Article in En | MEDLINE | ID: mdl-37400251

Subject(s)

Neoplasms; Adult; Humans; Positron-Emission Tomography; Protein Kinase Inhibitors/therapeutic use; Protein Kinase Inhibitors/pharmacology; Mitogen-Activated Protein Kinase Kinases; Recurrence; Fluorodeoxyglucose F18; Proto-Oncogene Proteins B-raf/genetics

Key words

MAPK pathway; gene targeting; histiocytosis; myeloproliferative disorder; targeted therapy